Cargando…

CHIP‐associated mutant ASXL1 in blood cells promotes solid tumor progression

Clonal hematopoiesis of indeterminate potential (CHIP) is an age‐associated phenomenon characterized by clonal expansion of blood cells harboring somatic mutations in hematopoietic genes, including DNMT3A, TET2, and ASXL1. Clinical evidence suggests that CHIP is highly prevalent and associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiaoxiao, Sato, Naru, Shimosato, Yuko, Wang, Teh‐Wei, Denda, Tamami, Chang, Yu‐Hsuan, Yabushita, Tomohiro, Fujino, Takeshi, Asada, Shuhei, Tanaka, Yosuke, Fukuyama, Tomofusa, Enomoto, Yutaka, Ota, Yasunori, Sakamoto, Takeharu, Kitamura, Toshio, Goyama, Susumu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990791/ https://www.ncbi.nlm.nih.gov/pubmed/35133065 http://dx.doi.org/10.1111/cas.15294

Ejemplares similares

Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis
por: Asada, Shuhei, et al.
Publicado: (2018)

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation
por: Saika, Makoto, et al.
Publicado: (2018)

Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms
por: Tamura, Moe, et al.
Publicado: (2019)

Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway
por: Fujino, Takeshi, et al.
Publicado: (2021)

Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation
por: Nagase, Reina, et al.
Publicado: (2018)

P407: MITOTIC FIDELITY IS A RESISTANCE MECHANISM TO DECITABINE IN MYELOID TUMORS.
por: Yabushita, Tomohiro, et al.
Publicado: (2023)

Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia
por: Hayashi, Yasutaka, et al.
Publicado: (2019)

IMPDH inhibition activates TLR‐VCAM1 pathway and suppresses the development of MLL‐fusion leukemia
por: Liu, Xiaoxiao, et al.
Publicado: (2022)

ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells
por: Inoue, Daichi, et al.
Publicado: (2018)

Epigenetics in normal and malignant hematopoiesis: An overview and update 2017
por: Goyama, Susumu, et al.
Publicado: (2017)

Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors
por: Tanaka, Yosuke, et al.
Publicado: (2022)

CRISPR/Cas9-mediated base-editing enables a chain reaction through sequential repair of sgRNA scaffold mutations
por: Fukushima, Tsuyoshi, et al.
Publicado: (2021)

Clonal hematopoiesis and associated diseases: A review of recent findings
por: Asada, Shuhei, et al.
Publicado: (2021)

SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS
por: Inoue, Daichi, et al.
Publicado: (2014)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
por: Ayoub, Maya C., et al.
Publicado: (2023)

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
por: Balasubramani, Anand, et al.
Publicado: (2015)

Functional and cancer genomics of ASXL family members
por: Katoh, M
Publicado: (2013)

ASXL1 plays an important role in erythropoiesis
por: Shi, Hui, et al.
Publicado: (2016)

ASXL1/2 mutations and myeloid malignancies
por: Medina, Edward A., et al.
Publicado: (2022)

Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network
por: Xia, Yu-Kun, et al.
Publicado: (2020)

ASXL1 mutations in Chinese patients with essential thrombocythemia
por: Nie, Yan-Bo, et al.
Publicado: (2018)

Loss of Asxl2 leads to myeloid malignancies in mice
por: Li, Jianping, et al.
Publicado: (2017)

Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish
por: Gjini, Evisa, et al.
Publicado: (2019)

T-Cells Null for the MED23 Subunit of Mediator Express Decreased Levels of KLF2 and Inefficiently Populate the Peripheral Lymphoid Organs
por: Kasper, Lawryn H., et al.
Publicado: (2014)

Expanding our knowledge of conditions associated with the ASXL gene family
por: Russell, Bianca, et al.
Publicado: (2013)

Role of ASXL1 mutation in impaired hematopoiesis and cellular senescence
por: Uni, Masahiro, et al.
Publicado: (2018)

Hyperventilation-athetosis in ASXL3 deficiency (Bainbridge-Ropers) syndrome
por: Dad, Rubina, et al.
Publicado: (2017)

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
por: Abdel-Wahab, Omar, et al.
Publicado: (2013)

Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1
por: Daou, Salima, et al.
Publicado: (2018)

Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish
por: Fang, Xiao, et al.
Publicado: (2021)

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
por: Wang, Liang, et al.
Publicado: (2021)

“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms
por: Gleitz, Hélène F.E., et al.
Publicado: (2022)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
por: Zenda, Sadamoto, et al.
Publicado: (2019)

BAP1/ASXL1 recruitment and activation for H2A deubiquitination
por: Sahtoe, Danny D., et al.
Publicado: (2016)

Asxl2(−/−) Mice Exhibit De Novo Cardiomyocyte Production during Adulthood
por: Brunner, Rachel, et al.
Publicado: (2016)

ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion
por: Madan, Vikas, et al.
Publicado: (2018)

Pathological ASXL1 Mutations and Protein Variants Impair Neural Crest Development
por: Matheus, Friederike, et al.
Publicado: (2019)

ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
por: Micol, Jean-Baptiste, et al.
Publicado: (2017)

Deregulation of tumor suppressive ASXL1−PTEN/AKT axis in myeloid malignancies
por: Cao, Lei, et al.
Publicado: (2020)

Identification of Candidate Biomarker ASXL2 and Its Predictive Value in Pancreatic Carcinoma
por: Wang, Gaoming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7p1njlkr2ikl0fd2jpsegb644n